Kindling Bio

Kindling Bio is pioneering a fundamentally different approach to immunotherapy, starting with childhood cancer, one of oncology’s greatest untapped opportunities. Its ‘Immune Flag’ viral gene-therapy platform creates a universal immune target in cancer, harnessing pre-existing immunity to drive tumour destruction. By unifying neglected paediatric cancers into a scalable beachhead, Kindling Bio unlocks a fast, capital-efficient path from a paediatrics to multi-billion-dollar adult oncology market expansion.